American Journal of Pathology, Vol. 164, No. 4, April 2004
Copyright © American Society for Investigative Pathology

Pathological Role of Large Intestinal IL-12p40 for the Induction of Th2-Type Allergic Diarrhea

Ayako Hino,*†‡ Mi-Na Kweon,*‡§
Kohtaro Fujihashi,† Jerry R. McGhee,† and
Hiroshi Kiyono*†‡

From the Division of Mucosal Immunology, Department of Microbiology and Immunology, Institute of Medical Science, The University of Tokyo, Tokyo, Japan; the Departments of Oral Biology and Microbiology,† The Immunobiology Vaccine Center, The University of Alabama at Birmingham, Birmingham, Alabama; the Mucosal Immunology Section,§ International Vaccine Institute, Seoul, Korea; and Core Research for Evolution Science and Technology,‡ Japan Science and Technology Corporation, Tokyo, Japan*

IL-12 consists of two disulfide-linked subunits, p40 and p35, that form functionally active heterodimers for the induction of Th1 cells. In contrast to IL-12 heterodimers, p40 monomers and homodimers possess inhibitory effects on Th1 cells leading to the creation of a Th2 environment. Although it has been shown that IL-12p40 acts as antagonist of IL-12p70 *in vitro*, no evidence is currently available whether IL-12p40 is functional *in vivo*. We now report that IL-12p40 plays an important pathological role in an intestinal allergic disease. A high expression of IL-12p40 protein was demonstrated in epithelial cells, dendritic cells, and macrophages in large but not small intestine of allergic diarrhea-induced mice. Interestingly, neutralization with anti-IL-12p40 mAbs reduced the incidence and delayed the onset of disease development. Lower levels of ovalbumin (OVA)-specific IgE Abs in serum were detected in anti-IL-12p40 mAb-treated mice than in control Ab-treated mice. The secretion of Th2 cytokines and eotaxin by the mononuclear cells isolated from the large intestine of anti-IL-12p40 mAb-treated mice was significantly decreased. Finally, the removal of the IL-12p40 gene resulted in complete inhibition of disease development. These results show that over-expression of IL-12p40 is an important contributing factor for the generation of the dominant Th2-type environment in the large intestine of mice with allergic diarrhea. *(Am J Pathol 2004, 164:1327–1335)*

In general, intestinal allergic reactions are provoked by the activation of allergen-specific Th2-type cells, excessive eosinophil and mast cell recruitment, and IgE Ab production.[1,2] We previously reported that systematically primed BALB/c mice developed severe diarrhea after repeated oral challenge with ovalbumin (OVA).[1] Diarrhea-induced mice revealed a Th2-type allergic response characterized by high levels of Ag-specific IgE Abs in serum, increased numbers of IgG1, IgA and IgE Abs in the large intestine, and high numbers of mast cells and eosinophils in the large intestine. Furthermore, large intestinal CD4$^+$ T cells isolated from mice with allergic diarrhea secreted IL-4, IL-5, and IL-13, but not IFN-γ. On the other hand, a murine model of eosinophilic gastrointestinal hypersensitivity induced by challenge with oral allergen, in the form of enteric-coated beads, resulted in marked allergen-induced IL-4 and IL-5 production and eosinophil accumulation in the small intestine. Although several interesting intestinal allergic models were recently reported,[2,3] the exact underlying molecular and cellular mechanisms remain to be elucidated.

In allergic asthma, allergen-specific T cells have been shown to also acquire the Th2 phenotype and to avoid from the Th1-type pathway.[4,5] A recent study has demonstrated that Th1/Th2 imbalance induced allergic disease at the level of transcription factors. Interestingly, a high expression of GATA-3 and/or a lack of T-bet signaling markedly influenced the development of allergic asthma.[6,7] In addition, the expression of not only Th2-type cytokine but also Th1-type cytokine (ie, IFN-γ or IL-12) played a critical role in murine dermatitis and asthma models.[8,9] It has also been demonstrated that natural killer (NK) cells, like Th2 cells, play an important role in the development of allergen-induced asthma.[9]

It has been suggested that antigen-presenting cells (APCs) play a crucial role in the skewing of Th1 and Th2 differentiation.[10,11] IL-12 is a heterodimeric cytokine composed of p40 and p35 which strongly promotes the differentiation of naive CD4$^+$ T cells to the Th1 phenotype and suppresses the synthesis of Th2-type cytokines.[12] IL-12 is produced primarily by APCs and the production is regulated by IL-10 and IFN-γ.[13,14] In addition, biological effects of IL-12 are counter-balanced by IL-12p40 itself, which binds to the receptor complex without induc-

Supported in part by a CREST grant from Japan Science and Technology Corporation (JST) and Grant-in-Aid from the Ministry of Education, Science, Sports and Culture and the Ministry of Health and Welfare of Japan and by US PHS grants DK 44240, AI 18958, AI 43197, and DE 12242.

Accepted for publication December 24, 2003.

Address reprint requests to Dr. Hiroshi Kiyono, Division of Mucosal Immunology, Department of Microbiology and Immunology, Institute of Medical Science, The University of Tokyo, 4-6-1 Shirokanedai, Minato-ku, Tokyo 108-8639, Japan. E-mail: kiyono@ims.u-tokyo.ac.jp.

ing intracellular signals.[15] Thus, murine IL-12p40 inhibits IL-12-mediated responses by means of the competitive binding to IL-12 receptor with an affinity similar to that of IL-12p70.[16,17] Further, IL-12p40 can behave as an IL-12p70 antagonist *in vivo*, delaying the allograft rejection of cardiac myoblast.[18] IL-12p40 transgenic mice also showed increased susceptibility to the malaria infection.[19]

With regard to allergic responses, a potential contribution of IL-12 has been suggested for the development of allergic asthma.[9,20] Mixed Th1- and Th2-associated cytokines, including IFN-γ, IL-2, IL-5, GM-CSF, and IL-12, were secreted by smooth muscle cells located in the sensitized airways of atopic asthma-induced mice.[21] A previous study demonstrated that IL-12p40 mRNA expression was detected in the lung tissue of mice with asthma.[21] However, the role of IL-12 in intestinal allergic disease has not yet been carefully examined. To investigate the potential roles of IL-12 in intestinal hypersensitivity, we have assessed the expression pattern of IL-12p40 or IL-12p35 in the intestinal tract of diarrhea-induced mice and examined the therapeutic effects of modulating IL-12 involvement in allergic diarrhea.

Materials and Methods

Mice

BALB/c mice were purchased from Japan Clea Company (Tokyo, Japan). Breeding pairs of IL-12p40-deficient [IL-12p40 knockout (KO)] mice were purchased from The Jackson Laboratories (Bar Harbor, ME), and colonies were established and maintained in the experimental animal facility at the University of Tokyo and the University of Alabama at Birmingham. All mice were 6 to 7 weeks of age at the beginning of individual experiments.

Antibodies

Recombinant murine IL-12 p40 and p70 were obtained from BD PharMingen (San Diego, CA). Biotin-anti-CD11b (M1/70, rat IgG2b) and biotin-anti-CD11c (HL3, hamster IgG) were also purchased from BD PharMingen. Biotin-SP-conjugated, affinity-purified anti-rat IgG (H+L) mouse $F(ab')_2$ and anti-hamster IgG(H+L) goat $F(ab')_2$ were obtained from Jackson ImmunoResearch Laboratories, Inc. (West Grove, PA). Anti-IL-12p40 (C17.8.20, rat IgG2a) was a generous gift from Dr. G. Trinchieri, Wistar Institute, Philadelphia, PA[22] and was purified from ascites on a protein G column (Pharmacia Biotech, Uppsala, Sweden). Purified rat IgG was purchased from Sigma Chemical, Inc. (St. Louis, MO).

Induction of Allergic Diarrhea

For the induction of allergic diarrhea, our well-established protocol was used as described previously.[1] Briefly, on the first day of the experiment (day 0), mice were primed by subcutaneous (SC) injection of 1 mg of OVA in Complete Freund Adjuvant (CFA) (Difco Laboratories, Detroit, MI). One week after the systemic priming (day 7), mice were repeatedly challenged with 50 mg of OVA by oral administration (PO) three times per week for several weeks.[1] These mice were sacrificed and analyzed within 1 and 2 hours after a total of 10 times of oral administration with OVA. In a timed kinetics study, mice were sacrificed at indicated intervals, ie, 0, 30 minutes, 1 hour, and 2 hours following the last oral administration of OVA. As controls, mice were repeatedly given oral OVA in phosphate-buffered saline (PBS) without systemic priming or were injected SC with 1 mg OVA in CFA without repeated oral challenge.

Treatment of Mice with Anti-IL-12p40

In vivo Ab treatment was performed as described previously.[23] Anti-IL-12p40 (C17.8.20, rat IgG2a) was a generous gift from Dr. G. Trinchieri, Schering-Plough Research Institute, Dardilly, France.[22] BALB/c mice were intraperitoneally administered with 0.5 mg to 2.0 mg of purified anti-IL-12p40 (C17.8) or control rat IgG (Sigma Chemicals, Inc.) per week for the duration of the experiment. Ab treatment was started 1 week before or at the time systemic priming with OVA in CFA. Among different concentrations tested, the protocol of 1 mg/mouse of per week was the most optimal condition. Further, when the mAb treatment schedule was compared between the start at 1 week before or at the same time as OVA systemic priming, an identical effect was noted in this study. Thus, the mAb anti-IL-12 (1 mg/mouse) was started on 1 week before the OVA systemic priming.

ELISA for OVA-Specific IgE Abs in Serum

To assess OVA-specific IgE Ab levels in serum, a sandwich ELISA system was adopted.[1] End-point titers of OVA-specific IgE Abs were expressed as the reciprocal $\log_2$ of the last dilution that showed a level of 0.1 higher absorbance than that of sera of non-immune mice as background.

Isolation of Mononuclear Cells and Cytokine-Specific ELISA Assay

To isolate mononuclear cells from small and large intestines, we used a enzymatic dissociation method.[24] Briefly, mononuclear cells were dissociated by collagenase from small and large intestines after the removal of Peyer's patches and were then subjected to a discontinuous Percoll gradient.[25] Mononuclear cells from small and large intestines were then co-cultured in the presence of 1 mg OVA. After 3 days of culture, the supernatant was collected and assayed for cytokines by using an ELISA Kit specific for IL-4 (Endogen, Woburn, MA), IL-5 (Amersham Pharmacia Biotech, Piscataway, NJ), IL-13 (R&D Systems, Minneapolis, MN) and eotaxin (Techne Corporation, Minneapolis, MN).

Table 1. Primers and Probes Used for Qualitative and Quantitative RT-PCR

		Conventional PCR*	
HPRT	primer	F	GTT GGA TAC AGG CCA GAC TTT GTT G
		R	GAG GGT AGG CTG GCC TAT AGG CT
IL-12p40	primer	F	ATG GCC ATG TGG GAG CTG GAG
		R	TTT GGT GCT TCA CAC TTC AGG
IL-12p35	primer	F	ACC CAG TTG GCC AGG GTC
		R	CAA GGC ACA GGG TCA TCA TC
		Real-time PCR†	
HPRT	primer	F	AAC TTT GCT TTC CCT GGT
		R	AGT CAA GGG CAT ATC CAA CA
	probe	FITC	CAG TAC AGC CCC AAA ATG GTT AAG GTTGC
		LCRed640	AGC TTG CTG GTG AAA AGG ACG TCT CG
IL-12p40	primer	F	AGA GGA GGG GTG TAA CCA G
		R	GGG AAC ACA TGC CCA CTT G
	probe	FITC	ACC GAA GTC CAA TGC AAA GGC GG
		LCRed640	AAT GTC TGC GTG CAA GCT CAG G
IL-12p35	primer	F	CCT GTG CCT TGG TAG CAT CT
		R	AGA CTG CAT CAG CTC ATC G
	probe	FITC	ACC AGA CAG AGT TCC AGG CCA TCA
		LCRed640	TGA TGG CCT GGA ACT CTG TCT GGT

*, Primers were designed based on the published sequence.[13]
†, Primers and probes were designed and produced by Nihon Gene Research Laboratories (Sendai, Japan).

Immunoprecipitation and Western Blot Analyses

For the detection of different forms of IL-12, intestinal tissue extracts were prepared as previously described with minor modifications.[26] Small and large intestines were removed, minced in cold PBS with protease inhibitor, homogenized, and incubated to allow cytokine release from the tissue. After centrifugation intestinal tissue extracts were subjected to the measurement of protein concentration and then pre-cleared with protein G Sepharose beads (Pharmacia Biotech, Uppsala, Sweden), subsequently incubated with anti-IL-12p40, mixed with protein G Sepharose beads. The beads were washed, subjected to SDS-PAGE under non-reducing condition. After electrophoresis, proteins were transferred to a polyvinylidene difluoride microporous membrane (PVDF Immobilon; Millipore, Bedford, MA) and the membrane was reacted with biotinylated anti-IL-12 (C17.8) followed by incubation with biotin-streptavidin complex (ABC-AP Kit; Vector Laboratories, Inc.). Visualization of the signal was performed by NBT/BCIP Substrate Kit (BioRad, Hercules, CA).

Analysis for IL-12 mRNA Accumulation

The expression of IL-12p40 or p35 in small and large intestines of mice was examined using conventional RT-PCR as previously described[13] and quantitative real-time PCR method using a Lightcycler (Roche Diagnostics, GmbH Mannheim, Germany), with some modifications.[27,28] The sequences of primers and probes for real-time PCR were designed by Nihon Gene Research Laboratories (Sendai, Japan) (Table 1). Total RNA was extracted by using TRIzol reagent (Invitrogen Life Technologies, Carlsbad, CA) and 2 μg of extracted RNA was subjected to RT reaction using Superscript II Reverse Transcriptase (Life Technologies).[14] Hypoxanthine phosphoribosyl transferase (HPRT) cDNA was used to standardize the total RNA content. The cDNA from each experimental sample was then subjected to the Lightcycler FastStart DNA Master Hybridization Probes Kit (Roche Diagnostics). The external standards of HPRT, IL-12p40, and IL-12p35 DNA prepared by PCR between 20 pg to 0.02 fentograms were used for the quantification of specific cDNA in each sample. The ratio of the p40 and p35 increase in experimental mice was calculated and compared with non-treated mice as follows; the ratio = (p40 or p35 mRNA amounts from experimental mice/HPRT mRNA amounts from experimental mice)/(p40 or p35 mRNA amounts from non-treated mice/HPRT mRNA amounts from non-treated mice).

Immunohistochemical Analysis

Following extensive washing, small and large intestines were fixed in 4% paraformaldehyde-PBS and treated with sucrose-gradient, frozen in OCT-embedding medium as previously described with minor modifications.[29] For IL-12p40 immunostaining, cryosections were subjected to antigen retrieval using 10 mmol/L citric buffer pH 6.0 for 5 minutes at 98°C. Slides were then blocked with normal mouse IgG and incubated with rat anti-IL-12p40 or control rat IgG for 16 hours at 4°C. The section were then treated with biotinylated goat anti-rat IgG F(ab′)$_2$ (Jackson ImmunoResearch Laboratories, Inc.), ABC-AP Kit, and red chromogen (Vector Red; Vector Laboratories, Inc.). For IL-12p35 immunostaining, we used goat anti-IL-12p35 (Santa Cruz, Inc., Santa Cruz, CA) or control goat IgG. The sections were then treated with biotinylated donkey anti-goat IgG F(ab′)$_2$ and ABC-AP Kit. In the case of surface marker staining, serial sections were incubated with anti-CD11b (M1/70, BD PharMingen) or anti-CD11c (HL3, BD PharMingen), biotinylated second anti-



Figure 1. Selective production of IL-12p40 by the large intestine of diarrhea-induced mice. In **A**, large intestinal tissues from diarrhea-induced mice were immunostained with anti-IL-12p40 mAb, anti-IL-12p35 mAb, or control IgG. Control non-disease mice section gave no signal above background (data not shown). In **B-1**, IL-12p40-specific mRNA was expressed selectively in the large intestine of mice with allergic diarrhea. In **B-2**, quantitive real-time PCR analysis of IL-12p40- and p35-specific mRNA expression was performed. The ratio was obtained as the level of IL-12p40 or p35 expression in non-treated mice as a scale of one. The detailed information for the expression of this ratio is described in the Materials and Methods section. In **C-E**, IL-12p40 was detected in MØ and DC and epithelial cells in the large intestine. The serial sections of the large intestine from diarrhea-induced mice were stained with anti-IL-12p40 mAb and anti-CD11b mAb (**C**), with anti-IL-12p40 mAb and anti-CD11c mAb (**D**). The **arrows** point to double-positive cells. Large intestinal epithelial cells were stained with anti-IL-12p40 mAb (**E**).

body and ABC-AP. The color reaction was developed using Vector Red Substrate Kit I.

Statistical Analysis

Statistical analyses were performed by the two sample non-parametric Welch test with a significance level of 0.01 (**) for body weight and Ig levels, respectively. Mouse disease rates were determined using the Wilcoxon rank-sum test with a significance level of 0.01 (**). Values for cytokine-synthesis in the samples between anti-IL-12 p40-treated and control antibody-treated mice were analyzed by using Student's *t*-test at *P* values of <0.01(**).

Results

Detection of IL-12p40 Protein in the Large Intestine of Allergic Diarrhea Mice

To examine whether IL-12p40 was expressed in the large intestine of OVA-induced diarrhea mice, we analyzed IL-12 expression using a variety of available detection methods. First, we performed immunohistochemical analysis to directly demonstrate the enhanced IL-12p40 expression in the large intestine of mice with allergic diarrhea. As shown in Figure 1A, IL-12p40, but not IL-12p35, was expressed in the large intestine of diarrhea-induced mice. To further confirm enhanced expression of IL-12p40 in the large intestine of mice with diarrhea, we next performed IL-12-specific RT-PCR analysis. Interestingly, IL-12p40 mRNA was only detected in the large intestine of diarrhea-induced mice, not in control mice without the disease [eg, SC only or per oral challenge (PO) only; Figure 1B]. In contrast, IL-12p35 mRNA expression was detected in both groups of mice (Figure 1B-1). When IL-12-specific mRNA quantitative real-time PCR analysis was performed, high levels of IL-12p40-specific mRNA were noted in the large intestine of OVA-induced allergic diarrhea mice (Figure 1B-2). In contrast, the level of p35 did not vary among the four different groups including experimental diseased (SC/PO) and control non-diseased mice (non-treated, SC only, and PO only). Taken together, these results clearly indicate that IL-12p40, but not p35, was selectively enhanced at the levels of both mRNA and protein in the large intestine of allergic diarrhea mice.

Inasmuch as the induction of IL-12p40 selectively occurred in the large intestine of OVA-induced allergic diarrhea mice, it was important to determine which cell types produced IL-12p40 in the large intestine. Immunohistochemical analysis demonstrated that IL-12p40-producing cells were co-stained with anti-CD11b mAb [ie, macrophages (MØ)]. Further, $CD11c^{+}$ cells [ie, dendritic cells (DC)] were also positively stained for IL-12p40 (Figure 1, C and D). Further, some epithelial cells were also positive for IL-12p40 expression (Figure 1E). Taken together, these findings show that large intestinal macrophages, dendritic cells, and epithelial cells are responsi-



Figure 2. Induction of IL-12p40 homodimer in the large but not small intestine of diarrhea-induced mice. Large and small intestinal tissue extracts were subjected to immunopreciptation and Western blotting analysis using anti-IL-12p40 (C17.8) mAb under non-reducing conditions (**A**). The captions above the figure indicate the experimental mouse group receiving different *in vivo* treatments. Thus, the samples were obtained from SC/PO mice treated with C17.8 or control antibodies. Further, the samples were isolated from mice treated with PO only, SC only, or non-treated mice. The **arrow** points to IL-12p40 homodimer expression in the large intestine of diarrhea-induced mice. The data represent four independent experiments. In **B**, at the indicated times after oral administration of OVA, large intestinal tissue extracts isolated from diarrhea-induced mice were assayed for IL-12p40 by the same method as in **A**. In **C**, the large intestinal tissue extracts of diarrhea-induced mice were subjected to Western blotting with anti-IL-12p35 Ab as well as anti-IL-12p40. IL-12p70 protein was used as a positive control for the IL-12p35 detection system. As negative control, immunoprecipitation was performed without the tissue specimens (Ab only). The data represent three different experiments.

ble for the production of IL-12p40 at the disease site of OVA-induced allergic diarrhea.

The Western blotting method was adopted for the examination of IL-12 p40 expression in the small and large intestinal tissue extracts from OVA-induced allergic diarrhea mice within 1 to 2 hours after the last oral challenge. In the large intestine of diarrhea-induced mice, the 80kD form of IL-12 predominated clearly demonstrating the presence of IL-12p40 homodimer but not 70kD IL-12 heterodimer, in contrast to the environment observed in the large intestine of control mice or the small intestine of mice with/without diarrhea (Figure 2A). The multiple bands of p40 and p80 are the result of glycosylation heterogenity.[15] We thus analyzed three bands of p40 and three bands of p80 as specific bands. In the case of spleen, IL-12p40 was detected in control, healthy mice. The levels of IL-12p40 did not change after development of allergic diarrhea (data not shown). To examine the kinetics of the response, we next assessed the time course of IL-12p40 expression in the large intestine of the diarrhea-induced mice. The expression of IL-12p40 or p80 in the large intestine peaked between 1 and 2 hours after the last oral challenge, at the same time that severe symptoms of OVA-induced allergic diarrhea were ob-



Figure 3. Inhibition of allergic diarrhea disease by the treatment with anti-IL-12p40 mAb. In **A**, anti-IL-12p40 mAb (C17.8) treatment (**thin dashed line**) delayed the development of allergic diarrhea when compared with the rat IgG-treated group (**solid line**). Statistical differences were determined by Wilcoxon rank-sum test and are indicated by **, $P < 0.01$. Mice with SC only were used as controls (**thick dashed line**). In **B**, **left**, body weight was recovered in allergic diarrhea mice treated with anti-IL-12p40 mAb (C17.8). In **B**, **right**, OVA-specific IgE Abs were reduced in the serum of allergic diarrhea mice treated with anti-IL-12p40 mAb (C17.8). The data are expressed as the mean of ± SE and are representative of five independent experiments. Statistical differences between anti-IL-12p40 mAb and control rat IgG-treated mice are indicated as **, $P < 0.01$.

served (Figure 2B). These data suggest that there is an intimate relationship between the development of diarrhea and the expression of IL-12p40 in the large intestine.

To further confirm the expression of IL-12p80 or p40 instead of the p70 form, the protein extracts from the large intestine of the diarrhea-induced mice were immunoprecipitated with anti-IL-12p40 mAb and then Western blotting was performed using anti-IL-12p35 mAb. No molecular bands corresponding to IL-12p70 proteins were detected in the large intestine of diarrhea-induced mice, while predominant IL-12p40 protein was detected (Figure 2C). The large molecular weight band above the p70 and p80 bands was non-specific and was caused by the nature of antibody used in the immunoprecipitation, since the large molecular weight band was also seen following immunoprecipitation in the absence of tissue specimens (Ab only in Figure 2C). These results indicate that the secretion of IL-12p40, but not IL-12p70, in the large intestine is critically important in the development of OVA-induced allergic diarrhea.

Anti-IL-12p40 Treatment Reduced the Symptoms of Allergic Diarrhea

Inasmuch as the preferential localization of IL-12p40 was observed in mice with allergic diarrhea, we next performed a neutralization experiment using anti-IL-12p40 mAb (C17.8). We observed a significant delay in the onset of diarrhea and reduced the frequency of diarrhea to 40% by treatment with anti-IL-12p40 mAb (Figure 3A). Obvious body weight loss was seen in control Ig-treated



Figure 4. *In vivo* treatment with anti-IL-12p40 (C17.8) reduced the predominant antigen-specific Th2 type responses by large intestinal mononuclear cells isolated from diarrhea-induced mice. The mononuclear cells isolated from the large intestine (1.5×10^5 cells/well) were cultured with OVA (1 mg/ml) for 3 days. Culture supernatants were harvested and then assayed for IL-4, IL-13, IL-5, and eotaxin by ELISA assay. These data are expressed as the mean ± SE and are representative of three independent experiments. The statistical differences between anti-IL-12p40 mAb and control antibody treated mice are indicated as **, $P < 0.01$.



A

Immunization	Mice	OVA-induced diarrhea (%)
SC / PO	WT	100
	IL-12p40 KO	0
SC only	WT	0

Figure 5. Suppression of allergic diarrhea development in IL-12p40 KO mice. In **A**, the incidence of allergic diarrhea was reduced in the IL-12p40 KO mice when compared with wild-type mice immunized subcutaneously and then given OVA repeatedly by the oral route (SC/PO). In **B**, the large intestinal LP mononuclear cells from IL-12p40 KO mice did not produce IL-4. Mononuclear cells isolated from the large intestine were restimulated with OVA for the assessment of IL-4 synthesis as described in Figure 4A. The data are expressed as the mean ± SE and represent three different experiments.

diarrhea mice, while treatment with anti-IL-12p40 mAb resulted in partial recovery from body weight loss (Figure 3B, left). In addition, high levels of OVA-specific IgE Abs were detected in the serum of diarrhea-induced mice treated with control Ab, whereas the mice treated with anti-IL-12p40 mAb showed low levels of OVA-specific IgE Abs (Figure 3B, right). These results indicate that treatment with anti-IL-12p40 mAb alters the environment from a disease-inducing one to one fastening recovery in OVA-induced allergic diarrhea.

Suppression of Intestinal Th2-Type Cytokine by Anti-IL-12p40 Treatment

To confirm decreased Th2-type responses in the large intestine after anti-IL-12p40 mAb treatment, we next examined antigen-induced cytokine production by the large intestinal mononuclear cells. Interestingly, the anti-IL-12p40 treatment resulted in decreased levels of OVA-induced Th2 cytokine synthesis including those of IL-4, IL-5, and IL-13 (Figure 4). Production levels of the Th2 cytokines were comparable to those of control mice without allergic diarrhea (SC only). In contrast to the alterations observed in OVA-induced Th2 cytokine synthesis, there was no difference in the level of IFN-γ production between the mice treated with anti-IL-12p40 mAb and control IgG (data not shown). We further confirmed that IL-4 producing cells were $CD4^+$ Th2 cells by intracellular staining (data not shown).

Finally, the level of eotaxin, a well-known chemokine for eosinophil recruitment in allergic disease,[30] was also examined, since our previous study demonstrated that the frequency of eosinophils was increased in the large intestine of allergic diarrhea mice.[1] Likewise, the level of eotaxin could also be presumed to be increased in the large intestine of allergic diarrhea mice (Figure 4). Interestingly however, the level of eotaxin synthesis was significantly decreased by the treatment with anti-IL-12p40 mAb (Figure 4). These results indicate that anti-IL-12p40 mAb inhibited the immunopathological Th2 cytokine environment of the large intestine in allergic diarrhea mice. Thus, an interesting scenario could be the presence of high levels of IL-12p40 monomer and/or homodimers instead of IL-12p70 in the disease site of OVA-induced allergic diarrhea mice. Therefore, treatment with anti-IL-12p40 mAb might result in the inhibition of Th2-type responses in the large intestine of allergic disease mice.

IL-12p40-Deficient Mice Do Not Develop Allergic Diarrhea

To directly confirm the pathological role of IL-12p40 in the development of allergic diarrhea, IL-12p40 knockout (KO) mice were used. IL-12p40 KO mice did not develop the allergic diarrhea completely (Figure 5A). OVA-induced IL-4 production by large intestinal LP mononuclear cells was not detected in IL-12p40 mice (Figure 5B). The levels of other Th2-type cytokines (IL-5 and IL-10) were also reduced in IL-12p40 KO mice (data not shown). Taken together, these results clearly show that IL-12p40 plays an important role in the development of this large intestinal allergic disease.

Discussion

Our present findings provide new, strong evidence for an immunopathological role for locally produced IL-12p40 in the development of OVA-induced allergic diarrhea. Here we demonstrate the high expression of IL-12p40, without IL-12p35, in the large intestine but not in the small intestine of mice with allergic diarrhea. These IL-12p40 were locally produced by large intestinal MØ, DC, and epithelial cells. Based on our knowledge, this is the first demonstration of the presence of IL-12p40 in the selected part of the intestinal tract (eg, large intestine) in mice with allergic diarrhea. Although IL-12 is thought to drive the Th1-dominant environment,[31] our present findings provide additional supportive evidence that IL-12p40 contributes to the generation of a Th2-dominant environ-

ment.[18,19] It should be noted that our results directly demonstrate the *in vivo* immunopathological contribution of locally produced mucosal IL-12p40 to the development of OVA-induced diarrhea. Thus, the anti-IL-12p40 treatment reduced the incidence of OVA-induced allergic diarrhea. An attractive explanation would be that large intestinal MØs and DCs as well as epithelial cells contribute to the development of pathological Th2-dominant responses by the production of IL-12p40 in OVA-induced allergic diarrhea. Thus, the administration of anti-IL-12p40 resulted in the inhibition of the locally produced, mucosal IL-12p40-created, pathological Th2 condition, leading to the reduction of disease development.

Our present and previous results clearly show that large intestinal antigen-specific Th cells produce high levels of Th2 cytokine in OVA-induced allergic diarrhea.[1] The presence of monomeric or dimeric forms of IL-12p40, behaving as an antagonist to IL-12p70, is an additional contributing factor for the creation of a dominant pathological Th2 environment. Thus, the severe symptoms of allergic diarrhea were reduced by treatment with anti-IL-12p40 mAb, since the production of Th2 cytokines was significantly decreased in the large intestine. Overall, IL-12p40-supported, Th2-type cytokine synthesis plays a critical and pathological role in the induction of allergic reactions in large intestinal tissues. Although we do not have any specific explanation for the generation of IL-12p40 at the disease site, one possibility could be antigen overload in the intestinal tract. Our previous study demonstrated that oral administration of high doses of OVA induced Th2-mediated allergic diarrhea in systematically pre-sensitized BALB/c mice.[1] In contrast, low doses of oral OVA failed to induce allergic diarrhea. It was also shown that high doses of OVA peptide increased the numbers of naive $CD4^+$ T cells with Th2-like phenotype, which in turn produced dramatically large amounts of IL-4.[32] Therefore, high doses of oral antigen may create an immunological environment favoring Th2 cell development. To support this view, it has also been shown that high doses of oral antigen preferentially inhibit IFN-γ-producing Th1-type cells.[1] Further, the dose of antigen can determine whether Th1- or Th2-type cells are generated by antigen-presenting cells including DC.[33] Taken together, these findings allow us to postulate that an overload of oral antigen may direct mucosal antigen-presenting cells, including DC and MØ, and epithelial cells, to produce monomeric or dimeric forms of IL-12p40 instead of IL-12p70.

IL-12 has been considered as an inhibitory factor for allergic responses induced by preferential Th2-cytokine production. Indeed, endogenous rIL-12 decreased IgE levels and Th2 cytokine production induced by allergic reaction.[34] In contrast, IL-12 has also been shown to be involved in the pathological phase of mucosa-associated allergic diseases of the respiratory tract. In the murine asthma model, IL-12 contributed to the recruitment of eosinophils into the respiratory tract via the induction of VCAM-1 on local vascular epithelial cells.[35] Thus, the deletion of the IL-12 gene (p40) resulted in a substantial reduction in the airway recruitment of eosinophils and in the expression of VCAM-1 when compared with wild-type mice exhibiting an asthma-like reaction induced by systemic sensitization followed by nasal OVA.[36] In addition, selective overexpression of IL-12p40 was noted in airway epithelial cells and bronchoalveolar lavage fluids of patients with asthma.[20] Our present findings also demonstrate that the locally produced p40 form of IL-12 was associated with the development of OVA-induced allergic diarrhea. Thus, IL-12p40 was preferentially expressed only in the large intestine of allergic diarrhea mice. In addition to these results generated through the characterization of an asthma model, our present finding suggests a critical role for IL-12, especially that of p40-associated molecules, for the development of allergic diseases including asthma and food allergy.

The treatment with anti-IL-12p40 mAbs effectively reduced the incidence as well as the severity of allergic diarrhea, an effect most likely due to an alteration in the dominant immunopathological Th2-type response to a Th1-type environment. To support this view, locally over-expressed IL-12p40 may compete with the well-known Th1 promoter IL-12p70 and IL-23 (p40/p19).[37–39] To this end, it has been shown that endogenous IL-12p40 can overcome the Th1-promoting activity of IL-12p70 and/or IL-23.[18] In this regard, our recent and separate study showed that IL-23p19-specific mRNA expression was not detected in either diseased or healthy BALB/c mouse groups (data not shown). The results suggest that IL-23 dose not play an important role in the development of our diarrhea model. Therefore, treatment with anti-IL-12p40 antibody likely eliminated the antagonistic effect of IL-12p40 at the local site, perhaps leading to the creation of an IL-12p70 environment for the initiation of down-regulation of Th2 responses. An alternative explanation would be that anti-IL-12p40 mAb used in this experiment may possess a higher affinity for the monomeric or dimeric form of IL-12 than for the IL-12p70 heterodimer. Although our emphasis has been on the inhibitory effects of anti-IL-12p40 mAb for the prevention of allergic diarrhea, one must accept the fact that complete prevention of disease development was never achieved through use of mAbs. A possible explanation for this finding could be that anti-IL-12p40 mAb inhibited Th1 induction of IL-12p70 in addition to IL-12p40. Thus, this alteration of a Th2 dominant environment and shift to one of a Th1-type may partially occur in the large intestine of mice with allergic diarrhea. To support this possibility, the mAb used in these experiments has been shown to neutralize IL-12p70 in addition to IL-12p40.[13,14] In addition, the experiments using IL-12p40 KO mice suggest that the absence of IL-12p40 results in a complete failure to develop allergic diarrhea. It clearly shows that IL-12p40 play a critical role in the development of this disease. However, one alternative and simple expectation would be that an IL-12p40 deficiency may lead to the creation of Th2 environment due to the lack of Th1 inducing IL-12p70. Thus, it may lead to the more susceptible condition for the development of Th2-mediated diarrhea. Although we do not have any specific data to negate the latter possibility, one possible explanation would be that the deficiency of IL-12p70 formation in IL-12p40 KO mice lead to the lack of ability to active antigen presenting cells. IL-12p70 deficiency may

result in the absence of induction antigen-specific T cell response including the pathological Th2-type cells. It has been shown that IL-12 or IL-12-induced IFNγ can directly activate antigen presenting cells.[40] To address the issue, a series of interesting experiment would be the adaptive transfer of large intestinal MØ, DC, and epithelial cells into IL-12p40 and/or p35 KO mice. These experiments are, of course, planned for our future study.

Recently, it has been suggested that IL-12 is also one of the key cytokines for the regulation of the intestinal immune response.[41] Mouse IL-12p40 is produced as monomer and homodimer five to ninety times as frequently as IL-12p70 *in vivo* and *in vitro*,[40,42] implying the existence of additional immunological roles for IL-12p40. An interesting possibility would be that excess production of the monomeric and/or the homodimeric form of IL-12p40 could be a key contributing factor to the maintenance of immunological homeostasis at the mucosal compartment. Interestingly, our present findings demonstrate that over-expression of IL-12p40 occurred only in the large but not the small intestine following oral exposure to high doses of protein antigen. At the present time, we cannot offer any specific explanation for this distinct localization of IL-12p40. However, an interesting possibility would be that the expression of negative regulators for IL-12, including sCD40L and IL-10R,[14,43] could differ between the small and large intestine. To support this possibility, epithelial cells have been shown to express CD40 and IL-10R.[34,44] Since the large intestinal tract is continuously exposed to overloaded microflora, the level of co-stimulatory molecule expression such as CD40 by large intestinal epithelial cells could be lower to avoid unnecessary inflammatory responses. Thus, the large intestinal tract may form an immunological environment favoring the generation of IL-12p40. This interesting possibility is currently being tested in our laboratory.

In summary, our results demonstrated that locally produced IL-12p40 contribute to the Th2 cell generation of pathological polarization in the large intestine of OVA-induced allergic diarrhea. This study provides the first evidence for the association of over-expressed IL-12p40 from intestinal epithelial cells, DC and MØ, in the development of allergic diarrhea. Thus, the application of anti-IL-12p40 mAb resulted in the reduction of disease incidence and severity. Further, the disease development was completely eliminated in the deletion of IL-12p40 gene. Taken together, our studies provide an opportunity to consider that anti-IL-12p40 mAbs may be an alternative therapeutical regimen for the control of allergic intestinal disease.

Acknowledgments

We thank members of the Mucosal Immunology Group at Osaka University, The University of Tokyo and The University of Alabama at Birmingham, Immunobiology Vaccine Center for their helpful comments, Dr. Kimberly K. McGhee for editorial help, and Ms. Kelly Stinson and Ms. Sheila Turner for their help in the preparation of this manuscript.

References

1. Kweon MN, Yamamoto M, Kajiki M, Takahashi I, Kiyono H: Systemically derived large intestinal CD4+ Th2 cells play a central role in STAT6-mediated allergic diarrhea. J Clin Invest 2000, 106:199–206
2. Hogan SP, Mishra A, Brandt EB, Royalty MP, Pope SM, Zimmermann N, Foster PS, Rothenberg ME: A pathological function for eotaxin and eosinophils in eosinophilic gastrointestinal inflammation. Nat Immunol 2001, 2:353–360
3. Mishra A, Hogan SP, Brandt EB, Rothenberg ME: Peyer's patch eosinophils: identification, characterization, and regulation by mucosal allergen exposure, interleukin-5, and eotaxin. Blood 2000, 96:1538–1544
4. Sampath D, Castro M, Look DC, Holtzman MJ: Constitutive activation of an epithelial signal transducer and activator of transcription (STAT) pathway in asthma. J Clin Invest 1999, 103:1353–1361
5. Shirakawa T, Enomoto T, Shimazu S, Hopkin JM: The inverse association between tuberculin responses and atopic disorder. Science 1997, 275:77–79
6. Das J, Chen CH, Yang L, Cohn L, Ray P, Ray A: A critical role for NF-κB in GATA3 expression and TH2 differentiation in allergic airway inflammation. Nat Immunol 2001, 2:45–50
7. Finotto S, Neurath MF, Glickman JN, Qin S, Lehr HA, Green FH, Ackerman K, Haley K, Galle PR, Szabo SJ, Drazen JM, De Sanctis GT, Glimcher LH: Development of spontaneous airway changes consistent with human asthma in mice lacking T-bet. Science 2002, 295:336–338
8. Spergel JM, Mizoguchi E, Oettgen H, Bhan AK, Geha RS: Roles of TH1 and TH2 cytokines in a murine model of allergic dermatitis. J Clin Invest 1999, 103:1103–1111
9. Korsgren M, Persson CG, Sundler F, Bjerke T, Hansson T, Chambers BJ, Hong S, Van Kaer L, Ljunggren HG, Korsgren O: Natural killer cells determine development of allergen-induced eosinophilic airway inflammation in mice. J Exp Med 1999, 189:553–562
10. Rodriguez-Sosa M, Satoskar AR, Calderon R, Gomez-Garcia L, Saavedra R, Bojalil R, Terrazas LI: Chronic helminth infection induces alternatively activated macrophages expressing high levels of CCR5 with low interleukin-12 production and Th2-biasing ability. Infect Immun 2002, 70:3656–3664
11. Jankovic D, Liu Z, Gause WC: Th1- and Th2-cell commitment during infectious disease: asymmetry in divergent pathways. Trends Immunol 2001, 22:450–457
12. Yoshimoto T, Kojima K, Funakoshi T, Endo Y, Fujita T, Nariuchi H: Molecular cloning and characterization of murine IL-12 genes. J Immunol 1996, 156:1082–1088
13. Hino A, Nariuchi H: Negative feedback mechanism suppresses interleukin-12 production by antigen-presenting cells interacting with T helper 2 cells. Eur J Immunol 1996, 26:623–628
14. Hino A, Igarashi O, Tagawa YI, Iwakura Y, Nariuchi H: Interferon-γ priming is not critical for IL-12 production of murine spleen cells. Cytokine 2000, 12:12–20
15. Heinzel FP, Hujer AM, Ahmed FN, Rerko RM: In vivo production and function of IL-12 p40 homodimers. J Immunol 1997, 158:4381–4388
16. Wang X, Wilkinson VL, Podlaski FJ, Wu C, Stern AS, Presky DH, Magram J: Characterization of mouse interleukin-12 p40 homodimer binding to the interleukin-12 receptor subunits. Eur J Immunol 1999, 29:2007–2013
17. Ling P, Gately MK, Gubler U, Stern AS, Lin P, Hollfelder K, Su C, Pan YC, Hakimi J: Human IL-12 p40 homodimer binds to the IL-12 receptor but does not mediate biologic activity. J Immunol 1995, 154:116–127
18. Piccotti JR, Chan SY, Li K, Eichwald EJ, Bishop DK: Differential effects of IL-12 receptor blockade with IL-12 p40 homodimer on the induction of CD4+ and CD8+ IFN-γ-producing cells. J Immunol 1997, 158:643–648
19. Yoshimoto T, Wang CR, Yoneto T, Waki S, Sunaga S, Komagata Y, Mitsuyama M, Miyazaki J, Nariuchi H: Reduced T helper 1 responses in IL-12 p40 transgenic mice. J Immunol 1998, 160:588–594
20. Walter MJ, Kajiwara N, Karanja P, Castro M, Holtzman MJ: Interleukin 12 p40 production by barrier epithelial cells during airway inflammation. J Exp Med 2001, 193:339–351
21. Hakonarson H, Maskeri N, Carter C, Grunstein MM: Regulation of TH1- and TH2-type cytokine expression and action in atopic asth-

matic sensitized airway smooth muscle. J Clin Invest 1999, 103:1077–1087
22. Wysocka M, Kubin M, Vieira LQ, Ozmen L, Garotta G, Scott P, Trinchieri G: Interleukin-12 is required for interferon-γ production and lethality in lipopolysaccharide-induced shock in mice. Eur J Immunol 1995, 25:672–676
23. Fujihira K, Nagata M, Moriyama H, Yasuda H, Arisawa K, Nakayama M, Maeda S, Kasuga M, Okumura K, Yagita H, Yokono K: Suppression and acceleration of autoimmune diabetes by neutralization of endogenous interleukin-12 in NOD mice. Diabetes 2000, 49:1998–2006
24. Fujihashi K, McGhee JR, Kweon MN, Cooper MD, Tonegawa S, Takahashi I, Hiroi T, Mestecky J, Kiyono H: γ/δ T cell-deficient mice have impaired mucosal immunoglobulin A responses. J Exp Med 1996, 183:1929–1935
25. Kweon MN, Fujihashi K, VanCott JL, Higuchi K, Yamamoto M, McGhee JR, Kiyono H: Lack of orally induced systemic unresponsiveness in IFN-γ knockout mice. J Immunol 1998, 160:1687–1693
26. Li L, Sad S, Kagi D, Mosmann TR: CD8Tc1 and Tc2 cells secrete distinct cytokine patterns in vitro and in vivo but induce similar inflammatory reactions. J Immunol 1997, 158:4152–4161
27. Stordeur P, Zhou L, Byl B, Brohet F, Burny W, de Groote D, van der Poll T, Goldman M: Immune monitoring in whole blood using real-time PCR. J Immunol Methods 2003, 276:69–77
28. Kinoshita N, Hiroi T, Ohta N, Fukuyama S, Park EJ, Kiyono H: Autocrine IL-15 mediates intestinal epithelial cell death via the activation of neighboring intraepithelial NK cells. J Immunol 2002, 169:6187–6192
29. Romijn HJ, van Uum JF, Breedijk I, Emmering J, Radu I, Pool CW: Double immunolabeling of neuropeptides in the human hypothalamus as analyzed by confocal laser scanning fluorescence microscopy. J Histochem Cytochem 1999, 47:229–236
30. Cuvelier SL, Patel KD: Shear-dependent eosinophil transmigration on interleukin 4-stimulated endothelial cells: a role for endothelium-associated eotaxin-3. J Exp Med 2001, 194:1699–1709
31. Trinchieri G: Interleukin-12: a cytokine produced by antigen-presenting cells with immunoregulatory functions in the generation of T-helper cells type 1 and cytotoxic lymphocytes. Blood 1994, 84:4008–4027
32. Hosken NA, Shibuya K, Heath AW, Murphy KM, O'Garra A: The effect of antigen dose on CD4+ T helper cell phenotype development in a T cell receptor-α β-transgenic model. J Exp Med 1995, 182:1579–1584
33. Ruedl C, Bachmman FB, Kopf M: The antigen dose determined T helper subset development by regulation of CD40 ligand. Eur J Immunol 2000, 30:2056–2064
34. Gavett SH, O'Hearn DJ, Li X, Huang SK, Finkelman FD, Wills-Karp M: Interleukin 12 inhibits antigen-induced airway hyper-responsiveness, inflammation, and Th2 cytokine expression in mice. J Exp Med 1995, 182:1527–1536
35. Kaminuma O, Fujimura H, Fushimi K, Nakata A, Sakai A, Chishima S, Ogawa K, Kikuchi M, Kikkawa H, Akiyama K, Mori A: Dynamics of antigen-specific helper T cells at the initiation of airway eosinophilic inflammation. Eur J Immunol 2001, 31:2669–2679
36. Wang S, Fan Y, Han X, Yang J, Bilenki L, Yang X: IL-12-dependent vascular cell adhesion molecule-1 expression contributes to airway eosinophilic inflammation in a mouse model of asthma-like reaction. J Immunol 2001, 166:2741–2749
37. Oppmann B, Lesley R, Blom B, Timans JC, Xu Y, Hunte B, Vega F, Yu N, Wang J, Singh K, Zonin F, Vaisberg E, Churakova T, Liu M, Gorman D, Wagner J, Zurawski S, Liu Y, Abrams JS, Moore KW, Rennick D, de Waal-Malefyt R, Hannum C, Bazan JF, Kastelein RA: Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12. Immunity 2000, 13:715–725
38. Camoglio L, Juffermans NP, Peppelenbosch M, te Velde AA, ten Kate FJ, van Deventer SJ, Kopf M: Contrasting roles of IL-12p40 and IL-12p35 in the development of hapten-induced colitis. Eur J Immunol 2002, 32:261–269
39. Belladonna ML, Renauld JC, Bianchi R, Vacca C, Fallarino F, Orabona C, Fioretti MC, Grohmann U, Puccetti P: IL-23 and IL-12 have overlapping, but distinct, effects on murine dendritic cells. J Immunol 2002, 168:5448–5454
40. Trinchieri G: Interleukin-12: a proinflammatory cytokine with immunoregulatory functions that bridge innate resistance and antigen-specific adaptive immunity. Annu Rev Immunol 1995, 13:251–276
41. MacDonald TT, Monteleone G: IL-12 and Th1 immune responses in human Peyer's patches. Trends Immunol 2001, 22:244–247
42. D'Andrea A, Rengaraju M, Valiante NM, Chehimi J, Kubin M, Aste M, Chan SH, Kobayashi M, Young D, Nickbarg E, Chizzonite R, Wolf SF, Trinchieri G: Production of natural killer cell stimulatory factor (interleukin 12) by peripheral blood mononuclear cells. J Exp Med 1992, 176:1387–1398
43. Wittmann M, Kienlin P, Mommert S, Kapp A, Werfel T: Suppression of IL-12 production by soluble CD40 ligand: evidence for involvement of the p44/42 mitogen-activated protein kinase pathway. J Immunol 2002, 168:3793–3800
44. Young LS, Eliopoulos AG, Gallagher NJ, Dawson CW: CD40 and epithelial cells: across the great divide. Immunol Today 1998, 19:502–506

Available online at www.sciencedirect.com
SCIENCE DIRECT
Vaccine 22 (2004) 3751–3761
Vaccine
www.elsevier.com/locate/vaccine

Non-toxic Stx derivatives from *Escherichia coli* possess adjuvant activity for mucosal immunity

Mari Ohmura-Hoshino [a,b], Masafumi Yamamoto [a,b,c], Yoshikazu Yuki [a,d], Yoshifumi Takeda [e], Hiroshi Kiyono [a,b,d,f,*]

[a] *Department of Microbiology and Immunology, Division of Mucosal Immunology, The Institute of Medical Science, The University of Tokyo, 4-6-1 Shirokanedai, Minato-ku, Tokyo 108-8639, Japan*
[b] *Department of Mucosal Immunology, Research Institute for Microbial Diseases, Osaka University, 1-3 Yamadaoka, Suita, Osaka 565-0871, Japan*
[c] *Department of Oral Medicine, Nihon University School of Dentistry at Matsudo, 2-870-1 Sakaecho-Nishi, Matsudo, Chiba 271-8587, Japan*
[d] *Core Research for Evolutional Science and Technology (CREST), Japan Science and Technology Corporation (JST), Tokyo, Japan*
[e] *Faculty of Human Life Science, Jissen Woman's University, 4-1-1 Osakaue, Hino-shi, Tokyo 191-8510, Japan*
[f] *Departments of Microbiology and Oral Biology, Immunobiology Vaccine Center, University of Alabama at Birmingham, AL, USA*

Received 6 November 2003; received in revised form 9 February 2004; accepted 2 March 2004

Available online 22 April 2004

Abstract

Both B subunit of Shiga toxin 1 (Stx1-B), which mediates the binding of toxin to the membrane, and mutant Stx1 (mStx1), which is a non-toxic double-mutated Stx1 harboring double amino acid substitutions in the A subunit, possess potent mucosal adjuvant activity. Nasal immunization of mice with ovalbumin (OVA) plus the Stx1-B or mStx1 induced OVA-specific serum IgG and mucosal IgA responses. IgG subclass analysis revealed that mStx1 and Stx1-B as mucosal adjuvants supported Ag-specific IgG1 followed by IgG2b Abs. The co-administration of either mStx1 or Stx1-B with OVA enhanced the production of IL-4, IL-5, IL-6 and IL-10 with low IFN-γ, by OVA-specific $CD4^+$ T cells. To better elucidate the mechanisms underlying mStx1's and Stx1-B's adjuvant activity, we next sought to examine whether or not dendritic cells (DC) residing in the nasopharyngeal-associated lymphoreticular tissue (NALT) were activated by nasal administration of Stx1-B or mStx1. We found that mice nasally administered with Stx1-B or mStx1 showed an up-regulation in the expression of CD80, CD86 and especially CD40 on NALT DCs. Taken together, these results suggest that non-toxic Stx derivatives could be effective mucosal adjuvants for the induction of Th2-type, $CD4^+$ T cell mediated, antigen-specific mucosal IgA and systemic IgG Ab responses, and that they likely owe their adjuvant activity to the up-regulation of co-stimulatory molecules including CD80, CD86 and CD40 on NALT DCs.
© 2004 Elsevier Ltd. All rights reserved.

Keywords: Stx; Adjuvant

1. Introduction

Adjuvants are key to the development of effective mucosal vaccine because they can compensate for the often poorly immunogenic nature of orally and nasally administered vaccine antigens by inducing vaccine antigen-specific humoral and/or cellular immune responses. Much of the protection available at mucosal surfaces such as the respiratory, gastrointestinal and urogenital tracts is provided by the production of secretory IgA (S-IgA) antibodies (Abs) which are effectively produced only when vaccine is administered by a mucosal route [1]. In an effort to develop new strategies to curb global infection, researchers in the field are currently trying to develop novel adjuvants which can be nasally or orally co-administered with vaccine antigen to maximize the induction of protective S-IgA antibodies.

Thus far, several bacterial enterotoxins including cholera toxin (CT) of *Vibrio cholerae* and heat labile enterotoxin (LT) of enterotoxigenic *Escherichia coli* have been identified as possessing strong immunoenhancing activity against co-administered protein antigen when given by the oral or nasal routes [2–5]. By eliciting antigen (Ag)-specific Th2-type $CD4^+$ T cell responses with high levels of IL-4 and IL-5 production, mucosally co-administerated CT enhances the generation of Ag-specific systemic IgG1, IgE and mucosal S-IgA responses [6]. In contrast, LT induces a mix of IFN-γ-producing $CD4^+$ Th1-type and IL-4-, IL-5-, IL-6-, and IL-10-secreting Th2-type cells for subsequent induction of serum IgG1, IgG2a, and mucosal S-IgA Ab

* Corresponding author. Tel.: +81-3-5449-5270; fax: +81-3-5449-5411.
E-mail address: kiyono@ims.u-tokyo.ac.jp (H. Kiyono).

0264-410X/$ – see front matter © 2004 Elsevier Ltd. All rights reserved.
doi:10.1016/j.vaccine.2004.03.034

responses [7]. Other bacterial toxins such as pertussis toxin and PT-9K/129G, the genetically detoxified derivative of pertussis toxin have also been shown to possess mucosal adjuvant activities [8,9]. Pertussis toxin potentiates both Th1 and Th2 responses to antigen co-injected via the systemic route [10]. The mucosal presentation of a chimeric molecule composed of the gp 120V3 loop region of the MN strain of HIV-1 and a non-toxic form of *Pseudomonas* exotoxin resulted in strong mucosal and systemic immune responses to an integrated HIV-Ag [11]. However, Shiga toxin (Stx) was found to possess immunogenicity but not adjuvant activity when given via the oral route [12].

Stx, which is generated by Stx-producing *E. coli* (STEC), is one of the major virulence factors for STEC infectious diseases. Stx is a holotoxin composed of an A subunit measuring approximately 32-kDa in non-covalent association with a pentameric ring of an identical B subunit, each with a molecular mass of 7.7-kDa [13]. The A subunit is the enzymatic component of the toxin and acts as a highly specific *N*-glycosidase enzyme hydrolyzing the bond between ribose and a single adenine residue found on a prominent loop structure in the 28S rRNA component of eukaryotic ribosomes [14,15]. The B subunits mediate the binding of toxin to the neutral glycolipids of cell membranes, globotriaosylceramide and globotetraosylceramide [16]. Stx is classified into two groups: Stx1, the amino acid sequence of which is identical to that of Shiga toxin: Stx2, which is immunologically distinct from Stx1 [17].

In an effort to develop a candidate for a vaccine against infectious diseases caused by enterohemorrhagic *E. coli*, we have previously used site-directed mutagenesis to generate E167Q & R170L (mStx1), a double mutant of Stx1, harboring double amino acid substitutions in its RNA *N*-glycosidase active center [18]. Due to these mutations, mStx1 lacks RNA *N*-glycosidase activity, cytotoxicity and mouse lethality [18]. In the present study, we have addressed whether or not mStx1 and Stx1-B elicit mucosal adjuvant activity when co-administered nasally with protein antigen. Furthermore, we have assessed the capability of nasally administered mStx1 and Stx1-B to activate dendritic cells (DC) in nasopharyngeal-associated lymphoreticular tissue (NALT). Our results suggest that both mStx1 and Stx1-B are effective mucosal adjuvants for the induction of Ag-specific Ab responses in both mucosal and systemic compartments. Moreover, when applied nasally, they are also capable of up-regulating co-stimulatory molecules including CD80, CD86 and CD40 on NALT DCs.

2. Materials and methods

2.1. Mice

C57BL/6 mice purchased from SLC (Shizuoka, Japan) or Cler Japan, Inc. (Tokyo, Japan) were maintained and bred in the experimental animal facility at Osaka University under pathogen-free conditions in microisolator cages. All mice were provided sterile food and water ad libitum. C57BL/6 mice were used in this study at 8–12 weeks of age.

2.2. Bacterial toxins

The mutant of Stx1 (mStx1), native (n)Stx1 and nStx2 were purified from *E. coli* MC 1061 strain M 23, strain 87-27 and strain Tp 8, respectively [18,19]. As described previously, purification steps included ion-exchange, chromatofocusing and HPLC as described previously [19]. The B subunit of Stx1 (Stx1-B) was derived from *Bacillus brevis* pNU212-VT1B and was purified by the use of ion-exchange and gel filtration [20].

The amount of endotoxin was measured in the toxin preparation with an Endospec-SP test (Seikagaku Co., Tokyo, Japan). The nStx1, nStx2, mStx1 and Stx1-B used in this study contained 7.03, 9.52, 34.0 and 3.05 pg of *lipopolysaccharide* (LPS) per 10 μg of protein, respectively. The range of these LPS contents (e.g. 3-35 pg/10 μg protein) has been shown to have no biological effect on the immune system [21,22].

2.3. Immunization protocol and sample collection

A standard nasal immunization protocol was used in this study [23]. Mice were nasally immunized on days 0, 7 and 14 with a 10 μl aliquot (5 μl per nostril) containing 100 μg of ovalbumin (OVA; Sigma, St. Louis, MO) alone or combined with various doses of mStx1, Stx1-B, nStx1 or nStx2 as mucosal adjuvants [23]. Saliva was obtained from mice following i.p. injection with 100 μl of 1 mg/ml pilocarpine (Sigma). Nasal washes were collected by gently flushing the nasal passage with 100 μl of sterile PBS [23].

2.4. Analysis of antibody responses

Ag-specific Ab titers in serum, saliva, and nasal washes were determined by ELISA as described previously [6,24]. Briefly, plates were coated with OVA (1 mg/ml) and blocked with 1% BSA in PBS. After the plates were washed, serial dilutions of serum, saliva, or nasal washes were added in duplicate. Following incubation, the plates were again washed and peroxidase-labeled goat anti-mouse μ, γ or α heavy chain-specific Abs [Southern Biotechnology Associates (SBA), Birmingham, AL] were added to appropriate wells. Finally, 3,3′,5,5′-tetramethylbenzidine (TMB) with H_2O_2 was added for color development.

For IgG subclass analysis, biotinylated rat monoclonal anti-mouse γ1 (G1-7.3), γ2a (R19-15), γ2b (R12-3) or γ3 (R40-82) heavy chain-specific Abs (BD PharMingen, San Diego, CA) and streptavidin-conjugated peroxidase (Vector Laboratories, Inc., Burlingame, CA) were employed. For the analysis of total IgE antibodies, OptEIA ELISA for IgE was used (BD PharMingen). Endpoint titers were expressed

as the reciprocal $\log_2$ of the last dilution giving an optical density at 450 nm (OD_{450}) of ≥ 0.1 above negative control.

2.5. Detection of Ag-specific Ab-forming cells (AFCs) by the enzyme-linked immunospot (ELISPOT) assay

In the ELISPOT assay, numbers of Ag-specific AFCs from various tissues including salivary glands, nasal passages and spleens were determined by direct counting of spots as previously described in detail [4,24]. Ninty-six-well nitrocellulose-based plates (MultiScreen-HA, Millopore Co., Bedford, MA) were coated with 1 mg/ml of OVA diluted in PBS for enumeration of Ag-specific AFC. Wells were blocked with RPMI1640 medium containing 10% FCS, HEPES buffer (15 mM), L-glutamine (2 mM), penicillin (100 U/ml), and streptomycin (100 μg/ml) (complete medium). Cells at various dilutions were added and incubated for 6 h at 37 °C in 5% CO_2 in moist air. Antigen-specific AFCs were detected with peroxidase-labeled anti-mouse μ, γ, or α Ab (SBA) and then visualized by adding the chromogenic substrate, 3-amino-9-ethylcarbazole (Moss. Inc., Pasadena, MD). Spots were counted with the aid of a dissecting microscope (SZH Zoom Stereo Microscope System, Olympus, Lake Success, NY).

2.6. OVA-specific $CD4^+$ T cell responses

$CD4^+$ T cells were purified from cervical lymph node (CLN) and splenic cell suspensions by use of the magnet-activated cell sorter system (Miltenyi Biotec) [24]. Cells were added to a nylon wool column (Polysciences, Warrington, PA) and incubated at 37 °C for 1 h to remove adherent cells. The $CD4^+$ T cell subset was then obtained by positive sorting using a magnetic bead separation system consisting of anti-CD4 monoclonal (m)Ab (clone GK1.5)-conjugated microbeads (MACS; Miltenyi Biotec). Purified $CD4^+$ T cells (>98% purity) were cultured at a density of 4×10^6 cells/ml with OVA (1 mg/ml) with T cell-depleted, irradiated (3000 rads) splenic feeder cells (8×10^6 cells/ml) and rIL-2 (10 units/ml; PharMingen) in complete medium [23]. The $CD4^+$ T cell cultures were incubated for 3 days at 37 °C in 5% CO_2 in air. Culture supernatants were then harvested for quantitation of secreted IFN-γ, IL-4, IL-5, IL-6 and IL-10 by a commercial AN'LYZA immunoassay kit (R&D Systems, Minneapolis, MN). To measure the levels of Ag-specific T cell proliferation, 0.5 μCi of $[^3H]$thymidine (Amersham Pharmacia Biotech) was added to individual cultures 18 h before termination, and the uptake of $[^3H]$thymidine in counts per minute (cpm) was determined by scintillation counting [25].

2.7. FACS analysis

Cells were analyzed by FACS (FACS Calibur & CellQuest; Becton Dickenson Co. Inc., San Jose, CA) using the following antibodies from BD PharMingen: fluorescerin isothiocyanate (FITC)-conjugated anti-mouse CD11c (clone HL3), phycoerythrin (PE)-conjugated anti-mouse CD80 (clone 16-10A1), PE-conjugated anti-mouse CD86 (clone GL1), PE-conjugated anti-mouse $I\text{-}A^b$ (clone AF6-120.1), and PE-conjugated CD40 (clone 3/23).

2.8. Isolation of NALT DC

NALT was isolated and then rinsed in complete medium [23] before being digested with collagenase D (400 Mandl units/ml; Roche, Indianapolis, IN), as previously described [26]. Briefly, NALT was incubated with collagenase D (400 Mandl units/ml) and DNase I (200 μg/ml; Roche) for 35 min at 37 °C in RPMI 1640 medium, and EDTA at a final concentration of 5 mM was added during the last 5 min of incubation. For the enrichment of DC, released cells were layered over a metrizamide gradient column (Accurate, Westbury, NY; 14.5 g of metrizamide added to 100 ml of complete medium) and centrifuged, and the low-density fraction was collected as DCs [27]. The enriched DC cells were counted and then stained with the appropriate monoclonal antibodies, as described above for FACS analysis.

2.9. Statistical analysis

The results are reported as mean ± one standard error (S.E.). Statistical significance ($P < 0.05$) was determined by Student's t-test and by the Mann–Whitney U-test of unpaired samples.

3. Results

3.1. Induction of Ag-specific systemic Ab responses by nasal administration of OVA and mStx1 or Stx1-B

We began by assessing whether nasal co-administration of newly developed non-toxic Stx1 derivatives such as mStx1 or Stx1-B would provide mucosal adjuvant activity for the induction of Ag-specific Ab responses (Fig. 1A). Mice were nasally immunized with an optimal dose of OVA in the presence or absence of different concentrations of the adjuvant candidates. Although all doses of mStx1 tested in this study (e.g. 0.1–20 μg) provided the adjuvant activity, administration of 0.5 μg of mStx1 resulted in the highest OVA-specific IgM and IgG Ab responses among several doses tested (data not shown). Of all the dosages of Stx1-B tested (e.g. 0.1–20 μg), the administration of 5 μg of Stx1-B produced the most impressive serum IgM and IgG anti-OVA Ab responses. Although a dosage of 0.5 μg of the native form of Stx1 (nStx1) resulted in some adjuvant activity, high doses (e.g. 2 μg) of nStx1 proved universally lethal to mice ($n = 5$) (data not shown). Due to its lethality, native Stx1 does not make a practical mucosal adjuvant candidate. That same lethality also makes nStx1 unsuitable for subcutaneous co-administration, as we found in an earlier study (unpub-



Fig. 1. Mucosal adjuvant activity of Stx1 derivatives for the induction of systemic antibody responses. OVA-specific serum IgM, IgG and IgA Ab responses (A), IgG subclass Ab responses (B) and total IgE responses (C) were examined and compared in serum of mice nasally immunized with OVA plus mStx1 or Stx1-B. Groups of C57BL/6 mice were nasally immunized with 100 μg of OVA plus 0.5 μg of Stx1 mutant (dotted bar) (E167R & R170L; mStx1), or 5 μg of Stx1-B (black bar) as mucosal adjuvant or with OVA alone (white bar) on days 0, 7 and 14. Serum samples were collected at day 21 and examined for OVA-specific IgM, IgG and IgA Abs, OVA-specific IgG subclass Ab responses and total IgE by ELISA. The results are expressed as the mean ± S.E.M. from five to six mice per group and from a total of three separate experiments.

lished data). In summary, we found mStx and Stx1-B to be the best candidates for possible mucosal adjuvants, since an optimal dose of 0.5 or 5 μg, respectively, induced serum IgM, IgG and relatively low IgA anti-OVA Ab responses (Fig. 1A). Consequently, the remainder of our experiments focused on the mucosal adjuvant activity of these two forms of non-toxic derivatives. As expected, antigen-specific Ab responses were low after nasal immunization with OVA alone (Fig. 1A). Analysis of OVA-specific IgG subclass responses revealed that co-administration of mStx1 or Stx1-B resulted in a major IgG subclass response with IgG1 subclass appearing, followed by IgG2b (Fig. 1B). The levels of total IgE were not statistically changed between mice immunized with OVA and Stx1 derivatives and those administered OVA alone (Fig. 1C). Further, nasal immunization of OVA and Stx1 derivatives did not mount for antigen-specific IgE antibodies (Stx1-B: 6.85 ± 0.05 and mStx1: 6.80 ± 0.02) when compared with OVA alone (<6.0) (data not shown).

When antigen-specific IgG antibody forming cells (AFC) in the spleen and cervical lymph node (CLN) of mice nasally immunized with OVA plus Stx1 derivatives were analyzed, significant numbers of OVA-specific IgG AFC were detected, confirming the results obtained by the characterization of OVA-specific serum Ab responses. In contrast, low numbers of OVA-specific IgG AFC were seen in spleen and CLN of mice given OVA alone (Fig. 2A).



Fig. 2. Analysis of OVA-specific antibody-forming cells (AFC) and OVA-specific CD4$^+$ T cell proliferative responses in mice nasally immunized with OVA and Stx1 derivatives. Mice were nasally immunized with OVA (100 μg) plus 0.5 μg of mStx1 (dotted bar), 5 μg of Stx1-B (black bar) or OVA alone (white bar). Mononuclear cells were isolated from spleen of nasally immunized mice at day 21 and examined by Ag-specific ELISPOT (A). Purified splenic CD4$^+$ T cells were co-cultured at a density of 2×10^6 cells/ml with 1 mg/ml of OVA, T cell-depleted, irradiated splenic feeder cells (4×10^6 cells/ml) in the presence of rIL-2 (10 U/ml) in complete medium for 3 days for the proliferation assay (B). A control culture consisting of CD4$^+$ T cells, feeder cells and rIL-2 (10 U/ml) resulted in a [^{3}H] thymidine incorporation of 160 ± 19 cpm. The results are expressed as the mean of stimulation index ± S.E.M. from five to six mice per group and from a total of three experiments.

3.2. Ag-specific mucosal IgA immune responses induced by the co-administration of mStx1 or Stx1-B as a mucosal adjuvant

It is important to note that nasal co-administration of mStx1 or Stx1-B supported the induction of OVA-specific IgA Ab responses in mucosal secretions. Thus, nasal immunization with OVA and an optimal dose of mStx1 resulted in the induction of antigen-specific IgA Abs in saliva and nasal washes (Fig. 3A). Furthermore, co-administered Stx1-B also induced the secretion of OVA-specific IgA antibodies in saliva and nasal washes. In contrast, IgA Abs were not induced in mice by nasal immunization with OVA alone (Fig. 3A). Analysis of antigen-specific AFC further demonstrated that nasally co-administered mStx1 or Stx1-B supported the induction of OVA-specific IgA AFC in nasal passages and salivary glands (Fig. 3B). These findings further support the notion that the nontoxic Stx1 derivatives possess mucosal adjuvanticity for the generation of antigen-specific mucosal IgA responses following nasal administration.

3.3. Non-toxic Stx1-derivatives induced OVA-specific CD4$^+$ T cell responses

When CD4$^+$ T cells from spleen and CLN of mice nasally immunized with OVA plus mStx1 or Stx1-B were restimulated with the antigen in vitro, the levels of OVA-specific proliferative responses were increased (Fig. 2B). Antigen-specific CD4$^+$ T cell responses were the highest in mice nasally immunized with OVA and Stx1-B, and next highest in those immunized with OVA and mStx1. In contrast, there was virtually no Ag-specific proliferation in CD4$^+$ T cells isolated from mice given OVA alone (Fig. 2B). These results suggest that Stx1-B and mStx1 are potential adjuvants for the induction of antigen-specific CD4$^+$ T cells in both mucosal (e.g., CLN) and systemic (e.g., spleen) tissues.

In the subsequent experiment, the production of IL-4, IL-5, IL-6, IL-10 and IFN-γ production by antigen-specific CD4$^+$ T cells was analyzed at the protein level (Fig. 4). Increased levels of IL-4, IL-5, IL-6 and IL-10 production with low IFN-γ were seen in OVA-stimulated CD4$^+$ T cell cultures prepared from CLN and spleen of mice nasally immunized with OVA plus Stx1-B. Similarly, CD4$^+$ T cells isolated from mice nasally immunized with OVA and mStx1 also resulted in the induction of IL-4, IL-5, IL-6 and IL-10 production. Mice co-administered with Stx1-B always showed higher levels of Th2-type cytokine production than did those co-administered with mStx1. Splenic and CLN CD4$^+$ T cells from mice given OVA alone produced neither IL-4 nor IL-5, and only minimal amounts of IL-6 and IL-10. Taken together, these results show that nasal administration of OVA plus Stx1-B or mStx1 as mucosal adjuvant induced antigen-specific Th2-type cytokine responses which in turn led to the generation of OVA-specific mucosal IgA as well as predominant serum IgG1 Ab responses.

3.4. Up-regulation of co-stimulatory molecules and CD40 on NALT DCs following nasal application of Stx1-B or mStx1

To examine whether the increased Ag-specific Th cell and B cell responses seen in these nasally immunized mice were associated with NALT DC activation, we next analyzed the expression of costimulatory molecules, MHC class II and CD40 on NALT DCs by flow cytometry 24 h after nasal administration of naïve mice with Stx1-B or mStx1 (Fig. 5). Approximately 65–75% of NALT DCs isolated from non-treated mice constitutively expressed the



Fig. 3. Mucosal adjuvant activity of Stx1 derivatives for the enhancement of Ag-specific IgA responses. Induction of OVA-specific mucosal IgA Ab responses in saliva and nasal washes (A) and of OVA-specific IgA AFCs in salivary glands and nasal passages (B) of mice nasally immunized with OVA and mStx1 or Stx1-B was examined. Groups of mice were nasally immunized with OVA plus 0.5 μg of Stx1 mutant (dotted bar), 5 μg of Stx1-B (black bar) or OVA alone (white bar). External secretions were collected at day 21 and examined for OVA-specific IgA Ab responses by ELISA. Mononuclear cells were isolated from salivary glands and nasal passages of nasally immunized mice at day 21 and examined for OVA-specific IgA AFCs by ELISPOT. The results are expressed as the mean ± S.E.M. from five to six mice per group and from a total of three experiments.

co-stimulatory molecules CD80 and CD86 (Fig. 5). Further, most of these NALT DC expressed MHC class II (data not shown), with approximately 55% of cells positive for CD40. Following nasal administration of mStx1 or Stx1-B, the levels of CD80, CD86, and CD40 expression on NALT DCs were increased. These findings suggest that nasally co-administered mStx1 and Stx1-B trigger partially activated NALT DC to fully activate.

4. Discussion

In this study, we have assessed a mutant form of Stx1 (E167Q & R170L; mStx1) and the B subunit of Stx1 (Stx1-B) as possible mucosal adjuvants for the induction of antigen-specific mucosal and systemic immune responses. Nasal co-administration of non-toxic Stx1-B or mStx1 as mucosal adjuvant induced high levels of mucosal anti-OVA IgA as well as serum IgG anti-OVA Ab responses. These two distinct forms of non-toxic Stx1 derivative preferentially induced antigen-specific Th2-type $CD4^+$ T cells which in turn generated OVA-specific IgG1 and IgA antibodies in the systemic and mucosal compartments, respectively. Our finding that mStx1 and Stx1-B enhanced CD80, CD86 and CD40 expression on NALT DCs also supports the mucosal adjuvanticity of these two forms of non-toxic Stx1 derivative for the induction of antigen-specific immune responses.

If practical application of the mucosal adjuvanticity of these two forms of non-toxic Stx1 derivative is to be realized,



Fig. 4. Analysis of Th1 (IFN-γ) and Th2 (IL-4, IL-5, IL-6 and IL-10) cytokine synthesis by antigen-specific $CD4^+$ T cells isolated from mice nasally immunized with OVA and Stx1 derivative. $CD4^+$ T cells were isolated from CLN and spleen of mice nasally immunized with OVA plus 0.5 μg of mStx1 (dotted bar), 5 μg of Stx1-B (black bar) or OVA alone (white bar). Purified splenic $CD4^+$ T cells were co-cultured at a density of 2×10^6 cells/ml with 1 mg/ml of OVA, T cell-depleted, irradiated splenic feeder cells (4×10^6 cells/ml) for 5 days. Culture supernatants were harvested and then analyzed for cytokine secretion using the IFN-γ-, IL-4-, IL-5-, IL-6- and IL-10-specific ELISA. The results are expressed as the mean ± S.E.M. from five to six mice per group and from a total of three experiments. $^*P < 0.05$ when compared with mice immunized with OVA alone.

safety must be made a priority. The non-toxicity of these Stx1 derivatives had already been previously demonstrated by us both in vitro and in vivo studies. [18,28]. For example, our recent results showed that both native Stx1 (nStx1) and native Stx2 (nStx2) but not Stx1-B induced apoptosis in human monocytic THP-1 cells of eukaryotic cells [29]. Another our recent studies also suggested that nStx1 and nStx2 induced apoptosis in murine bone marrow (BM) cultures while both mStx1 and Stx1-B supported maturation and activation of DC from BM cultures (our unpublished data). As described above in Section 3, nStx1 possessed some nasal adjuvant activity at a dosage of 0.5 μg but proved lethal at higher doses (e.g., 2 μg). Moreover, mice given as little as 0.1 μg of nStx2 did not survive (data not shown). In contrast, all mice given a dose as high as 20 μg of mStx1 or Stx1-B as mucosal adjuvant survived and exhibited high levels of co-administered antigen-specific systemic IgG and mucosal IgA responses. Further, mice given doses as high as 20 μg of mStx1 or Stx1-B showed no sign (e.g., weight loss) of mucosal toxicity (data not shown). These findings further demonstrated the non-toxicity of mStx1 and Stx1-B as mucosal adjuvants.

When given nasally, mStx1 and Stx1-B supported the generation of antigen-specific $CD4^+$ Th2 type responses via the production of IL-4, IL-5, IL-6 and IL-10 and thereby enhanced Ag-specific serum IgG1 and mucosal IgA responses (Figs. 1 and 3). Based on these results, both of these nasally delivered non-toxic derivatives of Stx1 could be categorized as Th2 inducer type adjuvants. Although the exact mechanism by which these non-toxic Stx1 derivatives induce Th2-type T cell responses remains to be elucidated, it is interesting to note that such Th2-type T cell responses are also preferentially induced by oral or nasal administration of CT [4,30]. One obvious explanation would be that the tendency of a toxin-related adjuvant to favor Th1 and/or Th2 cell-mediated immune responses would be affected by the quality of antigen-presenting cells associated with mucosal compartments. For example, mucosally administered CT preferentially enhances B7-2-mediated Ag presentation by B cells and/or macrophages [31,32]. To this end, Th1 or Th2 polarizing factors could be mainly classified into three categories: (1) the anatomical and histological location of DC and T cells, (2) the nature of microbial products (adjuvant) and (3) the nature of the antigen used for the im-



% of CD positive cells with high intensity

	CD80	CD86	CD40
Stx1-B	91.2 ± 7.6*	86.8 ± 3.2*	87.5 ± 1.0*
mStx1	80.8 ± 2.5*	93.9 ± 5.2*	74.7 ± 3.5*
PBS	73.5 ± 3.1	70.2 ± 5.1	56.5 ± 1.7

Fig. 5. Enhancement of CD40, CD80 and CD86 expressions on mucosal DC by nasal administration of non-toxic Stx1 derivatives. 24 h following nasal administration of an optimal dose of the Stx1 derivatives (0.5 μg of mStx1/mouse and 5 μg of Stx1-B/mouse), DC were examined by FACS to determine any alterations in CD40, CD80 and CD86 expression. The dotted line gives the background stain, omitting only the mAb used in the specific stain. Data are expressed as the mean ± S.E.M. and are obtained from a total of three independent experiments. * $P < 0.05$ when compared with control mice administered with PBS.

munization. For instance, the major T cell population in the lungs has been shown to be predominantly of the Th2 type [33], and Peyer's patches has been shown to be a site in which a high proportion of resting lymphocytes preferentially develop into Th2-type cells [34]. DCs in PP possess the ability to induce the differentiation of $CD4^+$ T cells into the Th2 pathway [35]. Thus, NALT DCs may also possess a similar ability to guide $CD4^+$ T cells to differentiate into Th2-type cells. Our data demonstrate that the expression of both CD80 and CD86 was enhanced on DC isolated from NALT of mice nasally administered with mStx1 or Stx1-B (Fig. 5). This pattern of co-stimulatory molecule expression suggests that mStx1- or Stx1-B-treated DC possess at least a capability for supporting Th2 type responses. Since PP, which along with NALT are the best- characterized mucosal inductive tissues, have been shown to contain three distinct subsets of DC including lymphoid, myeloid and double negative subsets [35], it is important to carefully examine the influence of the nasally administered Stx1 derivatives on different subsets of NALT DC and to determine the role of that influence in the creation of an environment conducive to Th2-type cell responses. To understand the importance of

the nature of the microbial compounds, one need only note that toxins such as CT and pertussis toxin have been shown to induce the development of DC type2 [36] and DC type1 [37], respectively, for the generation of Th2 and Th1 polarization, respectively [6,38]. In contrast, LT has been shown to support both Th1- and Th2-type responses [7]. Finally, the nature of the co-administered antigen itself may contribute to outcome of Th1 and/or Th2 polarization. Although CT is reported to be a potent Th2-inducing adjuvant, nasal vaccination with fimbriae and CT induced both Ag-specific Th1/Th2-type responses in $CD4^+$ T cells in mucosal effector tissues [39], while co-administration of tetanus toxoid or OVA resulted in the generation of antigen-specific Th2-type responses [30]. We still do not fully understand the exact molecular/cellular mechanisms by which nasal administration of Stx derivatives enhances Th2-type responses. However, given the promise and potency of non-toxic Stx derivatives as mucosal adjuvants, we are vigorously pursuing the elucidation of these mechanisms.

It is interesting to note that Stx1-B possessed a mucosal adjuvant activity equally as good as that of mStx1. Since Stx1-B binds to the Gb cell surface receptor, the signaling pathways through Gb3 may have immunomodulating activities. In this regard, it is well known that CT-B binds to GM1 ganglioside [40]. Further, other studies have demonstrated that GM1-mediated signaling enhances endocytosis as well as antigen presentation of APC including macrophages and DC. Further, glycosphingolipids such as GM1 have also been implicated as a delivery site for immune-enhancing signals [41]. This contention is supported by findings that rCT-B provides some mucosal adjuvant activity when given nasally [42,43]. Taken together, these findings suggest that interactions between Stx1-B and Gb3, like those between CT-B and GM1, may enhance immune responses. However, other studies including ours have reported that rCT-B does not appear to be as effective as the native form (e.g., holotoxin) in enhancing antigen-specific immune responses [30,44]. Thus, in general higher doses of rCT-B than of the native form have been used to demonstrate mucosal adjuvant activity [42,43]. Taken together, these previous studies along together with our results suggest that the immunomodulating activities induced by Stx1-B/Gb3 interactions may be much higher than those induced by CT-B/GM1 interactions. Studies are underway to elucidate this interesting possibility.

The results of this study have also shown that the administration of mStx1 harboring two mutations at the active site of RNA *N*-glycosidase activity fostered some adjuvant activity. High levels of serum Ag-specific IgG Ab and mucosal IgA Ab responses were induced in mice nasally immunized with OVA and mStx1. In order to develop a safe mucosal immunoenhancer, one that is non-toxic but retains adjuvanticity, a number of non-toxic mutant derivatives of CT or LT have been developed and characterized [25,30,32,45]. Early studies have suggested that ADP-ribosyltransferase activity is essential for the adjuvanticity of both LT and CT [44]. However, single amino acid-substituted mutants of CT S61F, E112K [25,30], P106S, S63K [46] and LT R7K [47], S63K [48], A72R [49] and R192G [50], which lack ADP-ribosyltransferase activity, were shown nevertheless to retain their adjuvanticity. Our results here support the latter group of findings by suggesting that toxic and adjuvant activities are separated from each other in the enzyme activity cleft of the bacterial toxins, including Stxs, CT and LT.

In the past, several different non-toxic mutant derivatives of CT or LT have been developed and characterized for their adjuvanticity [25,30,32,45]. In our separate study, it was shown that mutant CT (mCT of E112K and S61F) possessed adjuvanticity for supporting Th2 mediated IgA antibody responses [25,30]. Since these different forms of mutant CT and LT retain their adjuvanticity, we could consider to use one of these different forms of mutant CT and LT as a gold standard for mStx1 and Stx1-B. However, we have to realize the fact that Stx1 is completely different toxin molecule when compared with CT and LT in terms of biological activity and primary structure. For example, Stx has RNA *N*-glycosidase activity and cleaves a specific *N*-glycosidic bond in the 28S rRNA, thereby inhibiting the peptide chain elongation step of protein synthesis and ultimately causing cell death [51]. On the other hand, CT catalyzes ADP ribosylation of the G protein, Gsα which activates adenylate cyclase, resulting in elevation of intracellular cAMP levels, which causes secretion of water and chloride ions from epithelial cells into the small intestine [40]. The eukaryotic cell surface receptors for the members of Stx and CT families are globotriaosylceramide and GM1 ganglioside, respectively [40,51]. Thus, it might not be appropriate to compare Stx1 type and CT (or LT) type toxin-based adjuvants.

It has been suggested that the dose of adjuvant used for immunization can influence the adjuvant activity [52]. Thus, a simple notion is that adjuvanticity of manipulated toxin-based molecules can be demonstrated for every toxin-based adjuvant by increasing dose used for immunization. In the case of Stx1 derivatives, when a dose of 0.5 μg was employed for both Stx1-B and mStx1, the levels of serum Ag-specific Ab responses in Stx1-B-treated mice were lower than those seen in mStx1-treated groups (data not shown). However, the titer of Ag-specific Ab responses in Stx1-B-treated group was elevated in accordance to the increase of dose used (e.g., 5 μg) (data not shown). The adjuvanticity of mStx1 reached to plateau level at the dose of more than 0.5 μg (data not shown). Our data at least suggested that the dose effect of adjuvanticity was most obvious for Stx1-B when compared with that of mStx1. Inas much as a major purpose of our present study was to elucidate mucosal adjuvant activity of Stx1 derivatives including Stx1-B and mStx1, the optimal dose for these two molecules (5 and 0.5 μg, respectively) were determined and then employed for this study. Based on the present finding, our next goal is to determine the exact molecular mechanisms involved in mStx1 and Stx1-B mediated adjuvant activities. To investigate the differences between the mechanisms of adjuvanticity of mStx1 and Stx1-B, one possible

and interesting experiment would be to compare the induction and regulation of Th2 associated signaling events including GATA-3, c-maf or SLAT by mStx1 or Stx1-B since our result suggested that both Stx1-based adjuvants resulted in the induction of Th2 cell associated Ag-specific IgG1 and IgA responses (Figs. 1 and 3). To this end it has been shown that these signaling molecules are specifically associated with the Th2 cell differentiation [53,54].

In summary, this study has shown that nasal immunization with protein Ag plus mStx1 or Stx1-B as mucosal adjuvant elicits Ag-specific CD4^{+} Th2 cells in both mucosal and systemic tissues, and these cells in turn induce antigen-specific IgA and IgG Ab responses in the mucosal and systemic compartments, respectively. Non-toxic Stx derivatives could then be considered as new and promising candidates for mucosal adjuvants.

Acknowledgements

We appreciate the constructive comments regarding this work made by members of the Division of Immunology and Medical Zoology at Niigata University Graduate School of Medical and Dental Sciences and members of the Department of Mucosal Immunology, Research Institute for Microbial Diseases, Osaka University.

This study was supported by a grant from the Ministry of Health, Labor and Welfare, the Ministry of Education, Science, Sports and Culture, CREST, JST in Japan, and Special Coodination Funds for Promoting Science and Technology from the Ministry of Education, Culture, Sports, Science and Technology, the Japanese Government.. M.O. is supported by the Japanese Human Health Science Foundation.

All experiments described herein were approved by the appropriate local authorities. All procedures were in agreement with NIH guidelines for the handling of laboratory animals.

References

[1] Mestecky J, McGhee JR. Immunoglobulin A (IgA): molecular and cellular interactions involved in IgA biosynthesis and immune response. Adv Immunol 1987;40:153–245.

[2] Clements JD, Hartzog NM, Lyon FL. Adjuvant activity of *Escherichia coli* heat-labile enterotoxin and effect on the induction of oral tolerance in mice to unrelated protein antigens. Vaccine 1988;6(3):269–77.

[3] Elson CO, Ealding W. Generalized systemic and mucosal immunity in mice after mucosal stimulation with cholera toxin. J Immunol 1984;132(6):2736–41.

[4] Xu-Amano J, Kiyono H, Jackson RJ, et al. Helper T cell subsets for immunoglobulin A responses: oral immunization with tetanus toxoid and cholera toxin as adjuvant selectively induces Th2 cells in mucosa associated tissues. J Exp Med 1993;178(4):1309–20.

[5] Katz JM, Lu X, Young SA, Galphin JC. Adjuvant activity of the heat-labile enterotoxin from enterotoxigenic *Escherichia coli* for oral administration of inactivated influenza virus vaccine. J Infect Dis 1997;175(2):352–63.

[6] Marinaro M, Staats HF, Hiroi T, et al. Mucosal adjuvant effect of cholera toxin in mice results from induction of T helper 2 (Th2) cells and IL-4. J Immunol 1995;155(10):4621–9.

[7] Takahashi I, Marinaro M, Kiyono H, et al. Mechanisms for mucosal immunogenicity and adjuvancy of *Escherichia coli* labile enterotoxin. J Infect Dis 1996;173(3):627–35.

[8] Birnabaum S, Pinto M. Local and systemic opsonic adherent. Z Immunitatsforsch Exp Klin Immunol 1976;151(1–2):69–77.

[9] Roberts M, Bacon A, Rappuoli R, et al. A mutant pertussis toxin molecule that lacks ADP-ribosyltransferase activity, PT-9K/129G, is an effective mucosal adjuvant for intranasally delivered proteins. Infect Immun 1995;63(6):2100–8.

[10] Ryan M, McCarthy L, Rappuoli R, Mahon BP, Mills KH. Pertussis toxin potentiates Th1 and Th2 responses to co-injected antigen: adjuvant action is associated with enhanced regulatory cytokine production and expression of the co-stimulatory molecules B7- 1, B7-2 and CD28. Int Immunol 1998;10(5):651–62.

[11] Mrsny RJ, Daugherty AL, Fryling CM, FitzGerald DJ. Mucosal administration of a chimera composed of Pseudomonas exotoxin and the gp120 V3 loop sequence of HIV-1 induces both salivary and serum antibody responses. Vaccine 1999;17(11–12):1425–33.

[12] Suckow MA, Keren DF, Brown JE, Keusch GT. Stimulation of gastrointestinal antibody to Shiga toxin by orogastric immunization in mice. Immunol Cell Biol 1994;72(1):69–74.

[13] Donohue-Rolfe A, Acheson DW, Keusch GT. Shiga toxin: purification, structure, and function. Rev Infect Dis 1991;13(Suppl 4):S293–7.

[14] Endo Y, Tsurigi K, Yutsudo T, Takeda Y, Ogasawara T, Igarashi K. Site of action of a Vero toxin (VT2) from *Escherichia coli* O157: H7 and of Shiga toxin on eukaryotic ribosomes RNA *N*-glycosidase activity of the toxins. Eur J Biochem 1988;171:45–50.

[15] Saxena SK, O'Brien AD, Ackerman EJ. Shiga toxin, Shiga-like toxin II variant, and ricin are all single-site RNA *N*-glycosidases of 28 S RNA when microinjected into *Xenopus oocytes*. J Biol Chem 1989;264(1):596–601.

[16] Samuel JE, Perera LP, Ward S, O'Brien AD, Ginsburg V, Krivan HC. Comparison of the glycolipid receptor specificities of Shiga-like toxin type II and Shiga-like toxin type II variants. Infect Immun 1990;58(3):611–8.

[17] Stockbine N, Marques L, Newland J, Smith H, Holmes R, O'Brien A. Two toxin-converting phages from *Escherichia coli* O157: H7 strain 933 encode antigenically distinct toxins with similar biologic activities. Infect Immun 1986;53:135–40.

[18] Ohmura M, Yamasaki S, Kurazono H, Kashiwagi K, Igarashi K, Takeda Y. Characterization of non-toxic mutant toxins of Vero toxin 1 that were constructed by replacing amino acids in the A subunit. Microb Pathog 1993;15(3):169–76.

[19] Ito H, Yutsudo T, Hirayama T, Takeda Y. Isolation and some properties of A and B subunits of Vero toxin 2 and in vitro formation of hybrid toxins between subunits of Vero toxin 1 and Vero toxin 2 from *Escherichia coli* O157:H7. Microb Pathog 1988;5(3):189–95.

[20] Byun Y, Ohmura M, Fujihashi K, et al. Nasal immunization with *E. coli* verotoxin 1 (VT1)-B subunit and a nontoxic mutant of cholera toxin elicits serum neutralizing antibodies. Vaccine 2001;19(15–16):2061–70.

[21] Larsson R, Rocksen D, Lilliehook B, Jonsson A, Bucht A. Dose-dependent activation of lymphocytes in endotoxin-induced airway inflammation. Infect Immun 2000;68(12):6962–9.

[22] Ultrich JT, Cantrell JL, Gustafson GL, Rudbach JA, Hiernant JR. The adjuvant activity of monophsphoryl lipid A. Boca Raton, FL: CRC Press; 1991. p. 133–43.

[23] Yamamoto M, Briles DE, Yamamoto S, Ohmura M, Kiyono H, McGhee JR. A nontoxic adjuvant for mucosal immunity to pneumococcal surface protein A. J Immunol 1998;161(8):4115–21.

[24] VanCott JL, Staats HF, Pascual DW, et al. Regulation of mucosal and systemic antibody responses by T helper cell subsets, macrophages, and derived cytokines following oral immunization with live recombinant *Salmonella*. J Immunol 1996;156(4):1504–14.

[25] Yamamoto S, Takeda Y, Yamamoto M, et al. Mutants in the ADP-ribosyltransferase cleft of cholera toxin lack diarrheagenicity but retain adjuvanticity. J Exp Med 1997;185(7):1203–10.
[26] Swiggard W, Noncas MD, Witmer-Pack MD, Steinman RM. Enrichment of dendritic cells by plastic adherence and EA rosetting. In: Coligan JE, editor. Current Protocols in Immunology. Wiley, NY; 1991. p. 3.7.1–11.
[27] Macatonia SE, Knight SC, Edwards AJ, Griffiths S, Fryer P. Localization of antigen on lymph node dendritic cells after exposure to the contact sensitizer fluorescein isothiocyanate. Functional and morphological studies. J Exp Med 1987;166(6):1654–67.
[28] Austin PR, Hovde CJ. Purification of recombinant shiga-like toxin type I B subunit. Protein Exp Purif 1995;6(6):771–9.
[29] Kojio S, Zhang H, Ohmura M, Gondaira F, Kobayashi N, Yamamoto T. Caspase-3 activation and apoptosis induction coupled with the retrograde transport of shiga toxin: inhibition by brefeldin A. FEMS Immunol Med Microbiol 2000;29(4):275–81.
[30] Yamamoto S, Kiyono H, Yamamoto M, et al. A nontoxic mutant of cholera toxin elicits Th2-type responses for enhanced mucosal immunity. Proc Natl Acad Sci USA 1997;94(10):5267–72.
[31] Yamamoto M, Kiyono H, Yamamoto S, et al. Direct effects on antigen-presenting cells and T lymphocytes explain the adjuvanticity of a nontoxic cholera toxin mutant. J Immunol 1999;162(12):7015–21.
[32] Cong Y, Weaver CT, Elson CO. The mucosal adjuvanticity of cholera toxin involves enhancement of costimulatory activity by selective up-regulation of B7.2 expression. J Immunol 1997;159(11): 5301–8.
[33] Jones HP, Hodge LM, Fujihashi K, Kiyono H, McGhee JR, Simecka JW. The pulmonary environment promotes Th2 cell responses after nasal-pulmonary immunization with antigen alone, but Th1 responses are induced during instances of intense immune stimulation. J Immunol 2001;167(8):4518–26.
[34] Wilson AD, Bailey M, Williams NA, Stokes CR. The in vitro production of cytokines by mucosal lymphocytes immunized by oral administration of keyhole limpet hemocyanin using cholera toxin as an adjuvant. Eur J Immunol 1991;21(10):2333–9.
[35] Iwasaki A, Kelsall BL. Freshly isolated Peyer's patch, but not spleen, dendritic cells produce interleukin 10 and induce the differentiation of T helper type 2 cells. J Exp Med 1999;190(2):229–39.
[36] Gagliardi MC, Sallusto F, Marinaro M, Langenkamp A, Lanzavecchia A MT. Cholera toxin induces maturation of human dendritic cells and licences them for Th2 priming. Eur J Immunol 2000;30(8):2394–403.
[37] de Jong EC, Vieira PL, Kalinski P, et al. Microbial compounds selectively induce Th1 cell-promoting or Th2 cell-promoting dendritic cells in vitro with diverse th cell-polarizing signals. J Immunol 2002;168(4):1704–9.
[38] Ausiello CM, Fedele G, Urbani F, Lande R, Di Carlo B, Cassone A. Native and genetically inactivated pertussis toxins induce human dendritic cell maturation and synergize with lipopolysaccharide in promoting T helper type 1 responses. J Infect Dis 2002;186(3):351–60.
[39] Yanagita M, Hiroi T, Kitagaki N, et al. Nasopharyngeal-associated lymphoreticular tissue (NALT) immunity: fimbriae-specific Th1 and Th2 cell-regulated IgA responses for the inhibition of bacterial attachment to epithelial cells and subsequent inflammatory cytokine production. J Immunol 1999;162(6):3559–65.
[40] Spangler BD. Structure and function of cholera toxin and the related *Escherichia coli* heat-labile enterotoxin. Microbiol Rev 1992;56(4):622–47.
[41] Simons K, Ikonen E. Functional rafts in cell membranes. Nature 1997;387(6633):569–72.
[42] Isaka M, Yasuda Y, Kozuka S, et al. Induction of systemic and mucosal antibody responses in mice immunized intranasally with aluminium-non-adsorbed diphtheria toxoid together with recombinant cholera toxin B subunit as an adjuvant. Vaccine 1999;18(7–8):743–51.
[43] Tochikubo K, Isaka M, Yasuda Y, et al. Recombinant cholera toxin B subunit acts as an adjuvant for the mucosal and systemic responses of mice to mucosally co-administered bovine serum albumin. Vaccine 1998;16(2–3):150–5.
[44] Lycke N, Tsuji T, Holmgren J. The adjuvant effect of *Vibrio cholerae* and *Escherichia coli* heat-labile enterotoxins is linked to their ADP-ribosyltransferase activity. Eur J Immunol 1992;22(9):2277–81.
[45] Elson CO, Holland SP, Dertzbaugh MT, Cuff CF, Anderson AO. Morphologic and functional alterations of mucosal T cells by cholera toxin and its B subunit. J Immunol 1995;154(3):1032–40.
[46] Douce G, Fontana M, Pizza M, Rappuoli R, Dougan G. Intranasal immunogenicity and adjuvanticity of site-directed mutant derivatives of cholera toxin. Infect Immun 1997;65(7):2821–8.
[47] Douce G, Turcotte C, Cropley I, et al. Mutants of *Escherichia coli* heat-labile toxin lacking ADP-ribosyltransferase activity act as nontoxic, mucosal adjuvants. Proc Natl Acad Sci USA 1995;92(5):1644–8.
[48] Di Tommaso A, Saletti G, Pizza M, et al. Induction of antigen-specific antibodies in vaginal secretions by using a nontoxic mutant of heat-labile enterotoxin as a mucosal adjuvant. Infect Immun 1996;64(3):974–9.
[49] Giuliani MM, Del Giudice G, Giannelli V, et al. Mucosal adjuvanticity and immunogenicity of LTR72, a novel mutant of *Escherichia coli* heat-labile enterotoxin with partial knockout of ADP- ribosyltransferase activity. J Exp Med 1998;187(7):1123–32.
[50] Dickinson BL, Clements JD. Dissociation of *Escherichia coli* heat-labile enterotoxin adjuvanticity from ADP-ribosyltransferase activity. Infect Immun 1995;63(5):1617–23.
[51] Paton JC, Paton AW. Pathogenesis and diagnosis of Shiga toxin-producing *Escherichia coli* infections. Clin Microbiol Rev 1998;11(3):450–79.
[52] Rappuoli R, Pizza M, Douce G, Dougan G. Structure and mucosal adjuvanticity of cholera and *Escherichia coli* heat-labile enterotoxins. Immunol Today 1999;20(11):493–500.
[53] Kuo CT, Leiden JM. Transcriptional regulation of T lymphocyte development and function. Annu Rev Immunol 1999;17:149–87.
[54] Madrenas J. A SLAT in the Th2 signalosome. Immunity 2003;18(4):459–61.